Clinical trial
Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
NCT00493129 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00493129 |
|---|---|
| Title | Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) |
| Official title | ONTAK (Denileukin Diftitox) in Patients With Systemic Mastocytosis |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Systemic Mastocytosis |
| Intervention type | Drug |
| Interventions | Ontak (Denileukin Diftitox) |
| Enrollment | 8 |
| Start date | Jul 1, 2004 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Jun 28, 2007 |
| Last update posted | Feb 8, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: